Metastases to the central nervous system: Molecular basis and clinical considerations

被引:24
|
作者
Wanleenuwat, Pitchaya [1 ]
Iwanowski, Piotr [1 ]
机构
[1] Poznan Univ Med Sci, Dept Neurol, Przybyszewskiego 49, PL-60355 Poznan, Poland
关键词
Angiogenesis; Brain metabolism; Brain metastases; CNS metastases; Neuroinflammation; CELL LUNG-CANCER; ENDOTHELIAL GROWTH-FACTOR; BRAIN METASTASES; BREAST-CANCER; PROGNOSTIC-FACTORS; MATRIX METALLOPROTEINASES; KINASE INHIBITORS; TUMOR-CELLS; SURVIVAL; ANGIOGENESIS;
D O I
10.1016/j.jns.2020.116755
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Metastatic tumors are the most common malignancies of the central nervous system (CNS) in adults. CNS metastases are associated with unfavorable prognosis, high morbidity and mortality. Lung cancer is the most common source of brain metastases, followed by breast cancer and melanoma. Rising incidence is primarily due to improvements in systemic control of primary malignancies, prolonged survival and advances in cancer detection. Purpose: To provide an overview of the metastatic cascade and the role of angiogenesis, neuroinflammation, metabolic adaptations, and clinical details about brain metastases from different primary tumors. Methods: A review of the literature on brain metastases was conducted, focusing on the pathophysiology and clinical aspects of the disease. PubMed was used to search for relevant articles published from January 1975 through December 2019 using the keywords brain metabolism, brain metastasis, metastatic cascade, molecular mechanisms, incidence, risk factors, and prognosis. 146 articles met the criteria and were included in this review. Discussion: Some primary tumors have a higher tendency to metastasize to the CNS. Establishing a suitable metastatic microenvironment is important in maintaining tumor cell growth and survival. Magnetic resonance imaging (MRI) is a widely used tool for diagnosis and treatment monitoring. Available treatments include surgery, radiotherapy, stereotactic radiosurgery, chemotherapy, immunotherapy, and systemic targeted therapies. Conclusions: Prevention of metastases to the CNS remains a difficult challenge. Advances in screening of highrisk patients and future development of novel treatments may improve patient outcomes.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues
    Anna Sophie Berghoff
    Rupert Bartsch
    Adelheid Wöhrer
    Berthold Streubel
    Peter Birner
    Johan M. Kros
    Priscilla K. Brastianos
    Andreas von Deimling
    Matthias Preusser
    Acta Neuropathologica, 2014, 128 : 879 - 891
  • [32] Diagnosis and management of central nervous system metastases from breast cancer
    Chang, EL
    Lo, S
    ONCOLOGIST, 2003, 8 (05) : 398 - 410
  • [33] Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities
    Karz, Alcida
    Dimitrova, Maya
    Kleffman, Kevin
    Alvarez-Breckenridge, Christopher
    Atkins, Michael B.
    Boire, Adrienne
    Bosenberg, Marcus
    Brastianos, Priscilla
    Cahill, Daniel P.
    Chen, Qing
    Ferguson, Sherise
    Forsyth, Peter
    Oliva, Isabella C. Glitza
    Goldberg, Sarah B.
    Holmen, Sheri L.
    Knisely, Jonathan P. S.
    Merlino, Glenn
    Nguyen, Don X.
    Pacold, Michael E.
    Perez-Guijarro, Eva
    Smalley, Keiran S. M.
    Tawbi, Hussein A.
    Wen, Patrick Y.
    Davies, Michael A.
    Kluger, Harriet M.
    Mehnert, Janice M.
    Hernando, Eva
    PIGMENT CELL & MELANOMA RESEARCH, 2022, 35 (06) : 554 - 572
  • [34] Progress in the Biological Understanding and Management of Breast Cancer-Associated Central Nervous System Metastases
    Dawood, Shaheenah
    Gonzalez-Angulo, Ana M.
    ONCOLOGIST, 2013, 18 (06) : 675 - 684
  • [35] Treatments on the Horizon: Breast Cancer Patients with Central Nervous System Metastases
    Aaron Kaplan
    Min Jun Li
    Rachna Malani
    Current Oncology Reports, 2022, 24 : 343 - 350
  • [36] Central nervous system metastases in breast cancer patients administered trastuzumab
    Duchnowska, R
    Szczylik, C
    CANCER TREATMENT REVIEWS, 2005, 31 (04) : 312 - 318
  • [37] Management Paradigm of Central Nervous System Metastases in NSCLC: An Australian Perspective
    Lee, Chee Khoon
    Soon, Yu Yang
    Jeffree, Rosalind L.
    Joshi, Rohit
    Koh, Eng-Siew
    Lam, Wei-Sen
    Le, Hien
    Lwin, Zarnie
    Pinkham, Mark B.
    Siva, Shankar
    Ng, Evan
    John, Thomas
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (09):
  • [38] Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort
    Darlix, Amelie
    Louvel, Guillaume
    Fraisse, Julien
    Jacot, William
    Brain, Etienne
    Debled, Marc
    Mouret-Reynier, Marie Ange
    Goncalves, Anthony
    Dalenc, Florence
    Delaloge, Suzette
    Campone, Mario
    Augereau, Paule
    Ferrero, Jean Marc
    Levy, Christelle
    Fumet, Jean-David
    Lecouillard, Isabelle
    Cottu, Paul
    Petit, Thierry
    Uwer, Lionel
    Jouannaud, Christelle
    Leheurteur, Marianne
    Dieras, Veronique
    Robain, Mathieu
    Chevrot, Michael
    Pasquier, David
    Bachelot, Thomas
    BRITISH JOURNAL OF CANCER, 2019, 121 (12) : 991 - 1000
  • [39] Primary central nervous system lymphomas with massive intratumoral hemorrhage: Clinical, radiological, pathological, and molecular features of six cases
    Yamada, Seiji
    Muto, Jun
    Iba, Sachiko
    Shiogama, Kazuya
    Tsuyuki, Yuta
    Satou, Akira
    Ohba, Shigeo
    Murayama, Kazuhiro
    Sugita, Yasuo
    Nakamura, Shigeo
    Yokoo, Hideaki
    Tomita, Akihiro
    Hirose, Yuichi
    Tsukamoto, Tetsuya
    Abe, Masato
    NEUROPATHOLOGY, 2021, 41 (05) : 335 - 348
  • [40] Clinical presentation, risk factors and outcome of central nervous system metastasis vs stroke in cancer patients
    Cacho-Diaz, Bernardo
    Spinola-Marono, Hector
    Mendoza-Olivas, Laura G.
    CURRENT PROBLEMS IN CANCER, 2019, 43 (04) : 324 - 330